Clal Insurance’s UroGen Pharma URGN Stock Holding History

Clal Insurance’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-222,159	Closed	-$3.11M	–	140
2023 Q3	$3.11M	Sell	222,159 -307,229	-58%	-$4.93M	0.04%	84
2023 Q2	$5.48M	Hold	529,388	–	–	0.07%	91
2023 Q1	$4.89M	Hold	529,388	–	–	0.07%	91
2022 Q4	$4.7M	Hold	529,388	–	–	0.07%	104
2022 Q3	$4.41M	Hold	529,388	–	–	0.06%	112
2022 Q2	$4.34M	Hold	529,388	–	–	0.06%	112
2022 Q1	$4.61M	Hold	529,388	–	–	0.05%	114
2021 Q4	$5.03M	Hold	529,388	–	–	0.05%	120
2021 Q3	$8.9M	Hold	529,388	–	–	0.1%	115
2021 Q2	$8.08M	Hold	529,388	–	–	0.09%	115
2021 Q1	$10.3M	Hold	529,388	–	–	0.12%	113
2020 Q4	$8.91M	Hold	529,388	–	–	0.12%	94
2020 Q3	$10.2M	Hold	529,388	–	–	0.17%	88
2020 Q2	$13.8M	Hold	529,388	–	–	0.27%	78
2020 Q1	$9.44M	Buy	529,388 +511,722	+2,897%	+$13.8M	0.24%	76
2019 Q4	$529K	Sell	17,666 -511,722	-97%	-$14M	0.57%	46
2019 Q3	$12.6M	Sell	529,388 -24,390	-4%	-$797K	0.31%	66
2019 Q2	$19.9M	Sell	553,778 -1,196	-0.2%	-$44.1K	0.46%	52
2019 Q1	$20.5M	Buy	554,974 +155,712	+39%	+$6.53M	0.5%	47
2018 Q4	$17.2M	Buy	399,262 +89,262	+29%	+$4.01M	0.45%	45
2018 Q3	$14.6M	Hold	310,000	–	–	0.39%	38
2018 Q2	$15.4M	Buy	310,000 +26,500	+9%	+$1.54M	0.4%	34
2018 Q1	$14.1M	Buy	283,500 +279,039	+6,255%	+$14M	0.37%	31
2017 Q4	$166K	Buy	+4,461	New	+$159K	﹤0.01%	61

Other funds holding URGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Clal Insurance's URGN Position: Q4 2023 in Review

Clal Insurance sold out of UroGen Pharma (URGN) in Q4 2023, closing a stake of 222,159 shares — an estimated $3.11M sold.

Clal Insurance first reported a position in URGN in Q4 2017 and held it in 24 quarters. The position peaked at $20.5M in Q1 2019. 105 funds tracked by Wall St. Rank hold URGN as of Q4 2023.

Clal Insurance reported no remaining UroGen Pharma position as of Q4 2023 after selling out during the quarter.
Clal Insurance sold 222,159 UroGen Pharma shares in Q4 2023, an estimated $3.11M.
Clal Insurance first reported a position in UroGen Pharma in Q4 2017 and held it in 24 quarters.
Clal Insurance's UroGen Pharma position peaked at $20.5M in Q1 2019.
105 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2023.

Based on Clal Insurance's 13F filing for Q4 2023, filed 14 Feb 2024.